eMedicine Specialties > Dermatology > Diseases of the Dermis

Balanitis Xerotica Obliterans: Follow-up

Author: Noah S Scheinfeld, MD, JD, FAAD, Assistant Clinical Professor, Department of Dermatology, Columbia University; Consulting Staff, Department of Dermatology, St Luke's Roosevelt Hospital Center, Beth Israel Medical Center, New York Eye and Ear Infirmary; Private Practice
Coauthor(s): George C Keough, MD, Chief, Clinical Assistant Professor, Department of Medicine, Dermatology Service, Eisenhower Army Medical Center; Daniel S Lehman, MD, Fellow in Minimally Invasive Urology/Oncology, Department of Urology, Columbia University Medical Center
Contributor Information and Disclosures

Updated: Mar 17, 2008

Follow-up

Further Outpatient Care

  • Provide regular follow-up care to observe any changes in involved areas suggestive of malignancy.
  • Consider surgical intervention for symptoms or signs of urethral meatal stenosis.
  • Patients can be taught to dilate the urethral meatus at home if the BXO involves the meatus; this sometimes is useful.

Deterrence/Prevention

  • Early circumcision may decrease the risk of developing male genital LS; nearly all cases have been reported in uncircumcised patients.

Complications

  • As the disease progresses, urinary retention may be sufficient to lead to retrograde damage to the posterior urethra, bladder, and kidneys.
  • As previously noted, painful erections in some cases of male genital LS may limit sexual function.
  • Malignancies have been reported to occur in penile lesions (rare). Common signs and symptoms of penile malignancy include nodule or tumor growth, ulceration, blistering, hematuria, erythema, pain, purulent discharge, bleeding, lymphadenopathy, and failure to respond to treatment for presumptive inflammatory or infectious balanitis. For this reason, close follow-up care is indicated in order to quickly diagnose any malignant changes.

Prognosis

  • Male genital LS is chronic and often progressive. Regression or improvement of atrophic areas is unexpected.
  • Malignancies have been reported to arise in penile LS lesions (rare); most common cancers are SCC,16 adenosquamous carcinoma, and verrucous carcinoma.
    • A study of 86 uncircumcised men with genital LS revealed malignant changes (3 SCC, 1 SCC in situ, and 1 verrucous carcinoma) occurring in 5 (5.8%) subjects. The average time between diagnosis of LS and subsequent diagnosis of penile malignancy was 17 years.17
    • Notably, 4 of the 5 patients with malignant changes were found by polymerase chain reaction to have evidence of HPV-16 in their tissue specimens. It has been suggested that LS may promote HPV infection and perhaps the development of SCC.18

Miscellaneous

Medicolegal Pitfalls

  • Failure to diagnose male genital LS early is a potential pitfall.
    • Delay in diagnosis or follow-up of patients with urinary symptoms may lead to irreversible damage to the urinary system.
    • No singularly effective therapy exists; however, treatment with surgical and/or medical techniques should be quickly instituted upon diagnosis of this often progressive condition.
  • Failure to provide regular follow-up care is a potential pitfall. Care should include biopsy of ulcerating or nonhealing areas to detect malignancies (rare) developing from lesions of male genital LS.

Special Concerns

  • Men with genital LS may delay presenting to a physician because of fear or embarrassment. Accurate diagnosis, aided with appropriate biopsy, helps calm anxiety.
  • Goolamali and Pakianathan19 reported penile carcinoma arising in BXO in a 46-year-old white man; thus, if BXO is suspected or has occurred in the past, penile carcinoma should be excluded during the examination.
 


More on Balanitis Xerotica Obliterans

Overview: Balanitis Xerotica Obliterans
Differential Diagnoses & Workup: Balanitis Xerotica Obliterans
Treatment & Medication: Balanitis Xerotica Obliterans
Follow-up: Balanitis Xerotica Obliterans
Multimedia: Balanitis Xerotica Obliterans
References
[ CLOSE WINDOW ]

References

  1. Yardley IE, Cosgrove C, Lambert AW. Paediatric preputial pathology: are we circumcising enough?. Ann R Coll Surg Engl. Jan 2007;89(1):62-5. [Medline].

  2. Kizer WS, Prarie T, Morey AF. Balanitis xerotica obliterans: epidemiologic distribution in an equal access health care system. South Med J. Jan 2003;96(1):9-11. [Medline].

  3. Huntley JS, Bourne MC, Munro FD, Wilson-Storey D. Troubles with the foreskin: one hundred consecutive referrals to paediatric surgeons. J R Soc Med. Sep 2003;96(9):449-51. [Medline].

  4. Mallon E, Hawkins D, Dinneen M, Francics N, Fearfield L, Newson R, et al. Circumcision and genital dermatoses. Arch Dermatol. Mar 2000;136(3):350-4. [Medline].

  5. Chalmers RJ, Burton PA, Bennett RF, Goring CC, Smith PJ. Lichen sclerosus et atrophicus. A common and distinctive cause of phimosis in boys. Arch Dermatol. Aug 1984;120(8):1025-7. [Medline].

  6. Kiss A, Kiraly L, Kutasy B, Merksz M. High incidence of balanitis xerotica obliterans in boys with phimosis: prospective 10-year study. Pediatr Dermatol. Jul-Aug 2005;22(4):305-8. [Medline].

  7. Rossi E, Pavanello P, Franchella A. Lichen sclerosus in children with phimosis. Minerva Pediatr. Dec 2007;59(6):761-5. [Medline].

  8. Singh I, Ansari MS. Extensive balanitis xerotica obliterans (BXO) involving the anterior urethra and scrotum. Int Urol Nephrol. 2006;38(3-4):505-6. [Medline].

  9. Berglund RK, Angermeier KW. Combined buccal mucosa graft and genital skin flap for reconstruction of extensive anterior urethral strictures. Urology. Oct 2006;68(4):707-10; discussion 710. [Medline].

  10. Ebert AK, Vogt T, Rösch WH. Topical therapy of balanitis xerotica obliterans in childhood : Long-term clinical results and an overview. Urologe A. Dec 2007;46(12):1682-1686. [Medline].

  11. Kiss A. The response of clinical balanitis xerotica obliterans to the application of topical steroid-based creams. J Pediatr Surg. Mar 2006;41(3):606; author reply 606-7. [Medline].

  12. Ratz JL. Carbon dioxide laser treatment of balanitis xerotica obliterans. J Am Acad Dermatol. May 1984;10(5 Pt 2):925-8. [Medline].

  13. Dubey D, Sehgal A, Srivastava A, Mandhani A, Kapoor R, Kumar A. Buccal mucosal urethroplasty for balanitis xerotica obliterans related urethral strictures: the outcome of 1 and 2-stage techniques. J Urol. Feb 2005;173(2):463-6. [Medline].

  14. Levine LA, Strom KH, Lux MM. Buccal mucosa graft urethroplasty for anterior urethral stricture repair: evaluation of the impact of stricture location and lichen sclerosus on surgical outcome. J Urol. Nov 2007;178(5):2011-5. [Medline].

  15. Palminteri E, Berdondini E, Lazzeri M, Mirri F, Barbagli G. Resurfacing and reconstruction of the glans penis. Eur Urol. Sep 2007;52(3):893-8. [Medline].

  16. Pugliese JM, Morey AF, Peterson AC. Lichen sclerosus: review of the literature and current recommendations for management. J Urol. Dec 2007;178(6):2268-76. [Medline].

  17. Nasca MR, Innocenzi D, Micali G. Penile cancer among patients with genital lichen sclerosus. J Am Acad Dermatol. Dec 1999;41(6):911-4. [Medline].

  18. Drut RM, Gomez MA, Drut R, Lojo MM. Human papillomavirus is present in some cases of childhood penile lichen sclerosus: an in situ hybridization and SP-PCR study. Pediatr Dermatol. Mar-Apr 1998;15(2):85-90. [Medline].

  19. Goolamali SI, Pakianathan M. Penile carcinoma arising in balanitis xerotica obliterans. Int J STD AIDS. Feb 2006;17(2):135-6. [Medline].

  20. Bainbridge DR, Whitaker RH, Shepheard BG. Balanitis xerotica obliterans and urinary obstruction. Br J Urol. Aug 1971;43(4):487-91. [Medline].

  21. Beljaards RC, van Dijk E, Hausman R. Is pseudoepitheliomatous, micaceous and keratotic balanitis synonymous with verrucous carcinoma?. Br J Dermatol. Nov 1987;117(5):641-6. [Medline].

  22. Bingham JS. Carcinoma of the penis developed in lichen sclerosus et atrophicus. Br J Vener Dis. Oct 1978;54(5):350-1. [Medline].

  23. English JC 3rd, Laws RA, Keough GC, Wilde JL, Foley JP, Elston DM. Dermatoses of the glans penis and prepuce. J Am Acad Dermatol. Jul 1997;37(1):1-24; quiz 25-6. [Medline].

  24. Jenkins D Jr, Jakubovic HR. Pseudoepitheliomatous, keratotic, micaceous balanitis. A clinical lesion with two histologic subsets: hyperplastic dystrophy and verrucous carcinoma. J Am Acad Dermatol. Feb 1988;18(2 Pt 2):419-22. [Medline].

  25. Ledwig PA, Weigand DA. Late circumcision and lichen sclerosus et atrophicus of the penis. J Am Acad Dermatol. Feb 1989;20(2 Pt 1):211-4. [Medline].

  26. Meffert JJ, Davis BM, Grimwood RE. Lichen sclerosus. J Am Acad Dermatol. Mar 1995;32(3):393-416; quiz 417-8. [Medline].

  27. Meyrick Thomas RH, Ridley CM, Black MM. Clinical features and therapy of lichen sclerosus et atrophicus affecting males. Clin Exp Dermatol. Mar 1987;12(2):126-8. [Medline].

  28. Mikat DM, Ackerman HR Jr, Mikat KW. Balanitis xerotica obliterans: report of a case in an 11-year-old and review of the literature. Pediatrics. Jul 1973;52(1):25-8. [Medline].

  29. Peterson AC, Palminteri E, Lazzeri M, Guanzoni G, Barbagli G, Webster GD. Heroic measures may not always be justified in extensive urethral stricture due to lichen sclerosus (balanitis xerotica obliterans). Urology. Sep 2004;64(3):565-8. [Medline].

  30. Pietrzak P, Hadway P, Corbishley CM, Watkin NA. Is the association between balanitis xerotica obliterans and penile carcinoma underestimated?. BJU Int. Jul 2006;98(1):74-6. [Medline].

  31. Read SI, Abell E. Pseudoepitheliomatous, keratotic, and micaceous balanitis. Arch Dermatol. Jul 1981;117(7):435-7. [Medline].

  32. Staff WG. Urethral involvement in balanitis xerotica obliterans. Br J Urol. Apr 1970;42(2):234-9. [Medline].

  33. Wallace HJ. Lichen sclerosus et atrophicus. Trans St Johns Hosp Dermatol Soc. 1971;57(1):9-30. [Medline].

[ CLOSE WINDOW ]

Further Reading

[ CLOSE WINDOW ]

Keywords

BXO, penile lichen sclerosus, male genital lichen sclerosus, lichen sclerosus et atrophicus, LS, penile LS, sclerosing inflammatory dermatosis, Koebner phenomenon, vitiligo, thyroid disease, diabetes, alopecia areata,  pseudoepitheliomatous keratotic and micaceous balanitis, PKMB

[ CLOSE WINDOW ]

Contributor Information and Disclosures

Author

Noah S Scheinfeld, MD, JD, FAAD, Assistant Clinical Professor, Department of Dermatology, Columbia University; Consulting Staff, Department of Dermatology, St Luke's Roosevelt Hospital Center, Beth Israel Medical Center, New York Eye and Ear Infirmary; Private Practice
Noah S Scheinfeld, MD, JD, FAAD is a member of the following medical societies: American Academy of Dermatology
Disclosure: Optigenex Consulting fee Independent contractor

Coauthor(s)

George C Keough, MD, Chief, Clinical Assistant Professor, Department of Medicine, Dermatology Service, Eisenhower Army Medical Center
George C Keough, MD is a member of the following medical societies: American Academy of Dermatology and American Medical Association
Disclosure: Nothing to disclose.

Daniel S Lehman, MD, Fellow in Minimally Invasive Urology/Oncology, Department of Urology, Columbia University Medical Center
Disclosure: Nothing to disclose.

Medical Editor

Mark W Cobb, MD, Consulting Staff, WNC Dermatological Associates
Mark W Cobb, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, and American Society of Dermatopathology
Disclosure: Nothing to disclose.

Pharmacy Editor

Richard P Vinson, MD, Assistant Clinical Professor, Department of Dermatology, Texas Tech University School of Medicine; Consulting Staff, Mountain View Dermatology, PA
Richard P Vinson, MD is a member of the following medical societies: American Academy of Dermatology, Association of Military Dermatologists, Texas Dermatological Society, and Texas Medical Association
Disclosure: Nothing to disclose.

Managing Editor

Jeffrey Meffert, MD, Assistant Clinical Professor of Dermatology, University of Texas Health Science Center-San Antonio
Jeffrey Meffert, MD is a member of the following medical societies: American Academy of Dermatology, American Medical Association, Association of Military Dermatologists, and Texas Dermatological Society
Disclosure: Nothing to disclose.

CME Editor

Catherine Quirk, MD, Clinical Assistant Professor, Department of Dermatology, Brown University
Catherine Quirk, MD is a member of the following medical societies: Alpha Omega Alpha and American Academy of Dermatology
Disclosure: Nothing to disclose.

Chief Editor

William D James, MD, Paul R Gross Professor of Dermatology, University of Pennsylvania School of Medicine; Vice-Chair, Program Director, Department of Dermatology, University of Pennsylvania Health System
William D James, MD is a member of the following medical societies: American Academy of Dermatology and Society for Investigative Dermatology
Disclosure: elsevier Royalty Other; american college of physicians Honoraria Other

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.